Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Current Quarter	$0.03	Next Quarter	$0.01
Current Year	$-0.03	Next Year	$0.23
QoQ Growth	-66.7%	YoY Growth	+866.7%
3Y EPS CAGR	-45.6%	Target Price	$11.50
Consensus	Buy	Upside	+60.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XERS	$7.17	+2.28%	1.68M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XERS	$7.17	+2.3%	1.68M
3
4
5
6

XERS

XERS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Xeris Biopharma Holdings Inc. Data in Excel

Get Xeris Biopharma Holdings Inc. Data in Excel